English 
Japanese researchers have found a genetic change that seems to be very important in the way a rare type of liver tumor in children changes from a -harmful condition to a serious cancer. This discovery might help with testing and keeping track of the disease. It also might create a way to use precise medicine and tests that look for cancer in the blood.
The study was done by groups from Kyoto University, the University of Fukui and Shizuoka Childrens Hospital. They had help from the Liver Tumor Committee of the Japan Childrens Cancer Group. The results were shared in a journal called npj Precision Oncology on September 15 2026.
The scientists looked at a kind of cancer called embryonal sarcoma of the liver. This is a type of cancer in children. It can start from a -harmful tumor called mesenchymal hamartoma of the liver. Their work offers proof about how this change from a non-harmful to a harmful disease happens.
TP53 Becomes a Major Factor
The research team used samples from patients with both the -harmful and harmful tumors. They did a study of the molecules in the tumors. They found that both types of tumors have problems in a part of chromosome 19 called C19MC. When the scientists looked at TP53 a gene known for stopping cancer from growing there was a big difference.
TP53 problems were found in all the tumor cases. They were not found in the -harmful tumors. This helped the researchers see that getting TP53 problems is an important step in the change from mesenchymal hamartoma of the liver to undifferentiated embryonal sarcoma of the liver.
This discovery is important because the way this change happens was not known before. Learning about the steps could help scientists find children who are more likely to have the harmful change. It could also help in looking for ways to treat the disease.
Liquid Biopsy Might Change How We Watch the Disease
One of the useful ideas from the study is the use of liquid biopsy.
In some cases taking a tissue sample can be hard or dangerous. This is especially true when there is a risk of the tumor breaking during a test. The researchers made a system that can find and measure small amounts of cancer-related DNA and RNA in the blood. They were able to find the C19MC microRNA and TP53 problems, in blood samples from patients who might have tumors.
The technology also showed promise for checking how treatment is working. Scientists saw that the levels of the microRNA went down during cancer treatment. They were not found anymore after the tumor was completely removed. If this idea is tested in studies it could give doctors a way to track the disease and how well treatment is working. This way would not need to take tissue samples.
A Major Opportunity for Japan’s Precision Medicine Sector
The findings show how strong Japan’s collaborative efforts are in rare-disease research. UESL is a form of cancer. Because it is so uncommon individual hospitals struggle to gather cases and biological samples for large-scale studies. The JCCG Liver Tumor Committee played a role by connecting pediatric cancer centers across the country. This created a network of specimens that allowed researchers to carry out their study.
This kind of teamwork may become more essential as precision medicine moves forward. Rare cancers often need specialized data sets. Standard population-level research methods do not work well for them. By combining clinical networks with genomic analysis, molecular diagnostics and powerful computing researchers can get a clearer view of diseases that have been hard to understand.
For biotechnology and HealthTech companies this opens up chances in areas like genomic testing biomarker discovery, lab automation and data-analysis tools.
Implications for HealthTech and Drug Development
The research could also affect development over time. Finding TP53 abnormalities as a step in tumor growth gives scientists a clear molecular target to study. The researchers said this discovery could help develop treatments.
The results should not be seen as a ready-to-use treatment yet. The liquid-biopsy method still needs testing in prospective studies before it becomes part of regular medical practice. This difference matters a lot for childhood cancers. Clinical evidence takes time to build because there are few cases.
Still for Japan’s drug and biotech industries this study shows how molecular insights can link diagnostics and therapies. A better grasp of the causes behind disease can support both biomarker development and potential targets for future medicines.
Japan’s Broader Precision-Medicine Opportunity
The study shows how different technologies are coming together in cancer research: genomics, multi-omics, molecular diagnostics and liquid biopsy.
こちらもお読みください： 手話ロボット技術が、支援ロボットの新たな道を切り拓く
Japan already has strengths in medical research and biotech. Building ties between universities, hospitals, pharmaceutical firms and tech providers could help turn discoveries like this one into real-world diagnostic tools. The next step will be validation. The researchers plan to start studies to turn their findings into usable medical technologies.
If these efforts succeed the work could give doctors a way to diagnose and monitor UESL, a tough childhood cancer. It would also highlight the promise of blood-based molecular testing.
For Japan’s HealthTech sector the message is clear: progress in precision medicine does not mean finding new drugs. Better understanding of details and less-invasive diagnostics could be just as important, in changing how cancer is found tracked and treated.
日本語